Nov 7, 2016 2:35 pm EST Discovery of Cerecor Drug Candidate CERC-611 (LY3130481) Published in Nature Medicine
Oct 10, 2016 9:10 am EDT Cerecor to Present at the 15th Annual BIO Investor Forum in San Francisco on October 18th, 2016
Sep 26, 2016 9:10 am EDT Cerecor Announces Acquisition of TARP-γ8-AMPA Receptor Antagonist (CERC-611) from Lilly
Sep 21, 2016 9:10 am EDT Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder
Sep 12, 2016 9:10 am EDT Cerecor Enters Into a $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
Sep 6, 2016 9:10 am EDT Cerecor Announces Last Patient Enrolled in Phase 2 Clinical Trial with CERC-501 for Smoking Cessation
Sep 1, 2016 9:10 am EDT Cerecor to Present at 23rd Annual NewsMakers in the Biotech Industry Conference in New York City, September 9, 2016
Aug 29, 2016 9:10 am EDT Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical Trial in Smokers
Aug 22, 2016 9:10 am EDT Cerecor to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
